Phase II Study of Epacadostat (INCB024360) in Combination With Pembrolizumab in Patients With Locally Advanced/Metastatic Sarcoma
Latest Information Update: 20 May 2024
At a glance
- Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
- Indications Haemangioendothelioma; Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Sarcoma
- Focus Therapeutic Use
- 27 Feb 2024 Planned End Date changed from 1 Jan 2024 to 1 Jan 2025.
- 27 Feb 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Jan 2025.
- 27 Mar 2023 Results published in the Clinical Cancer Research